COVID-19 Vaccine and Therapeutic Trials ACTIV-ate in West Virginia

ACTIV clinical trials will evaluate the safety and efficacy of COVID-19 treatments and vaccines. Credit: iStock. Since the virus that causes COVID-19, known as SARS-CoV-2, was first reported in late 2019, scientists have launched hundreds of studies on strategies for diagnosis, prevention, and treatment. To prioritize the most promising vaccine and therapeutics candidates, streamline clinical trials, and coordinate regulatory processes, the National Institutes of Health (NIH) and the Foundation for the NIH have established the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. ACTIV brings together eight government entities, 20 biopharmaceutical companies, and four nonprofit organizations. The public-private partnership provides infrastructure, subject matter expertise, and funding to efficiently bring the most promising therapeutics and vaccines into clinical trials. Five ACTIV therapeutic trials are underway. NIGMS-supported Institutional Development Award Program Infrastructure for Clinical and Translational Research (IDeA-CTR) networks reach historically underserved areas and populations, which are important participants in such trials. Reaching Rural Residents Each dot on this map of West Virginia represents a primary care office or a research entity within the practice-based research network. Credit: West Virginia Clinical and Translational Science Institute. While several IDeA-CTR networks are joining one or more ACTIV ...
Source: Biomedical Beat Blog - National Institute of General Medical Sciences - Category: Research Authors: Tags: Being a Scientist Injury and Illness COVID-19 Infectious Diseases Medicines Scientific Process Source Type: blogs